

Investor Relations Contacts:

Patrick T. Mooney, M.D.
Chairman & CEO
Echo Therapeutics
508-530-0329

Lilian Stern
Stern Investor Relations
212-362-1200

Echo Therapeutics to Present at JMP Securities Healthcare Investor Conference

Franklin, MA – October 2, 2008 -- Echo Therapeutics, Inc. (OTCBB: ECTE) announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive Officer, will present at the JMP Securities Healthcare Investor Conference on October 7, 2008 at 10:00 am Eastern Standard Time. The presentation will occur live and will be held at Le Parker Meridien Hotel in New York City.

About Echo Therapeutics

Echo Therapeutics is focused on transdermal medical devices and specialty pharmaceuticals. Echo's Symphony™ tCGM System is in late-stage development as a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system for patients with Type 1 and Type 2 diabetes and for use in hospital critical care units. Echo's AzoneTS reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo's Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and its Prelude™ SkinPrep System, which incorporates leading-edge, needle-free skin permeation control. Echo expects the Symphony tCGM System to provide both diabetics and hospital professionals with a reliable, affordable, comfortable-to-wear, and easy-to-use, needle-free continuous glucose monitoring device.

Forward-Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's development plans, objectives, expectations and intentions, including, without limitation, statements regarding the Company's Symphony tCGM System and AzoneTS product candidates. Factors that could adversely affect Echo's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Echo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.



Echo Therapeutics, Inc
10 Forge Parkway
Franklin, MA 02038, USA
Tel: 508-553-8850
Fax: 508-553-8760
www.echotx.com

© 2002 - 2008 Echo Therapeutics, Inc. All rights reserved worldwide.